Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetes

J Diabetes Investig. 2023 Dec;14(12):1378-1382. doi: 10.1111/jdi.14071. Epub 2023 Aug 21.

Abstract

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (SU)-treated KCNJ11 permanent neonatal diabetes. The aim of this study was to assess for the first time the incretin hormone response to carbohydrate and protein/fat in adults with sulfonylurea-treated KCNJ11 permanent neonatal diabetes compared with that of controls without diabetes. Participants were given a breakfast high in carbohydrate and an isocaloric breakfast high in protein/fat on two different mornings. Incremental area under the curve and total area under the curve (0-240 minutes) for total GLP-1 and GIP were compared between groups, using non-parametric statistical methods. Post-meal GLP-1 and GIP secretion were similar in cases and controls, suggesting this process is adenosine triphosphate-sensitive potassium channel-independent. Future research will investigate whether treatments targeting the incretin pathway are effective in individuals with KCNJ11 permanent neonatal diabetes who do not have good glycemic control on sulfonylurea alone.

Keywords: GIP; GLP-1; Neonatal diabetes; incretin hormones; sulfonylurea.

MeSH terms

  • Adult
  • Blood Glucose / metabolism
  • Diabetes Mellitus*
  • Diabetes Mellitus, Type 2* / metabolism
  • Gastric Inhibitory Polypeptide
  • Glucagon / metabolism
  • Glucagon-Like Peptide 1
  • Humans
  • Incretins / therapeutic use
  • Infant, Newborn
  • Insulin / metabolism

Substances

  • Incretins
  • Glucagon
  • Insulin
  • Blood Glucose
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1

Supplementary concepts

  • Diabetes Mellitus, Permanent Neonatal